PYMX milestones
07:12 PDUFA V signed (GAIN Act)
2H:12 30063 initiate Phase IIb ABSSSI dose ranging study (single dose)
2H:12 Raise at least $15-20 MM (60056, Polycides, 30063 Int'l partnership)
YE:12 30063 initiate Phase II oral mucositis
2H:13 30063 Phase IIb ABSSSI results
4Q:13 30063 Phase II oral mucositis results
YE:13 30063 initiate Phase III ABSSSI pivotal trials
-----------
Year end 2013 is going to be the interesting time for this stock. If we can get past the current year fund raising with little or no dilution (big if), I think the stock could be in the $2.50 range in 18 months. That would give it a $435 MM f/d market cap, which is quite reasonable for two potential blockbuster indications about to enter relatively short pivotal trials. It would be a 600+% return in 18 months on the current stock price. Lot's of things have to go right, but I like the risk-reward. We've already got data on ABSSSI; just need to get some money, confirm the ABSSSI data with another trial and get a positive Phase II oral mucositis trial. Pretty easy right. :)
